nach oben

Metabolic Brain Disease

Erschienen in:

22.10.2020 | Review Article

Current and emerging therapeutic targets for Parkinson’s disease

verfasst von: Tanvi Pingale, Girdhari Lal Gupta

Erschienen in: Metabolic Brain Disease | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease (PD) is characterized by gradual neurodegeneration and forfeiture of dopamine neurons in substantia nigra pars compacta which ultimately leads to depletion of dopamine levels. PD patients not only display motor features such as rigidity, tremor, and bradykinesia but also non-motor features such as depression, anxiety, etc. Various treatments are available for PD patients such as dopamine replacement are well established but it is only partially or transiently effective. As these therapies not able to restore dopaminergic neurons and delay the development of Parkinson’s disease, therefore, the need for an effective therapeutic approach is crucial. The present review discusses a comprehensive overview of current novel targets for PD which includes molecular chaperone, neuroinflammation, mitochondrial dysfunction, neuromelanin, Ubiquitin-proteasome system, protein Abelson, Synaptic vesicle glycoprotein 2C, and Cocaine-amphetamine-regulated transcript, etc. These approaches will help to identify new targets for the treatment of disease and may provide a ray of hope for PD patient treatment.

Adler CH, Beach TG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Patel A, Sue LI, Serrano G, Jacobson SA, Davis K, Belden CM, Dugger BN, Paciga SA, Winslow AR, Hirst WD, Hentz JG (2017) GBA mutations in Parkinson disease: earlier death but similar neuropathological features. Eur J Neurol 24:1363–1368. https://doi.org/10.1111/ene.13395CrossRefPubMedPubMedCentral

Altmann V, Schumacher-Schuh AF, Rieck M, Callegari-Jacques SM, Rieder CR, Hutz MH (2016) Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson’s disease. Pharmacogenomics 17:481–488. https://doi.org/10.2217/pgs.15.183CrossRefPubMed

Angot E, Brundin P (2009) Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl. 3):S143–S147. https://doi.org/10.1016/S1353-8020(09)70802-8CrossRefPubMed

Auluck PK, Chan HYE, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 295:865–868. https://doi.org/10.1126/science.1067389CrossRefPubMed

Barja G, Herrero A (1998) Localization at complex I and mechanism of the higher free radical production of brain nonsynaptic mitochondria in the short-lived rat than in the longevous pigeon. J Bioenerg Biomembr 30:235–243. https://doi.org/10.1023/a:1020592719405CrossRefPubMed

Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182–217. https://doi.org/10.1124/pr.110.002642CrossRefPubMed

Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29:454–462. https://doi.org/10.1002/mds.25844CrossRefPubMedPubMedCentral

Berge-Seidl V, Pihlstrom L, Maple-Grodem J, Forsgren L, Linder J, Larsen JP, Tysnes OB, Toft M (2017) The GBA variant E326K is associated with Parkinson’s disease and explains a genome-wide association signal. Neurosci Lett 658:48–52. https://doi.org/10.1016/j.neulet.2017.08.040CrossRefPubMed

Betarbet R, Sherer TB, Greenamyre JT (2005) Ubiquitin proteasome system and Parkinson’s diseases. Exp Neurol 191(Suppl 1):S17–S27. https://doi.org/10.1016/j.expneurol.2004.08.021CrossRefPubMed

Blauwendraat C, Bras JM, Nalls MA, Lewis PA, Hernandez DG, Singleton AB (2018) International parkinson’s disease genomics consortium. Coding variation in GBA explains the majority of the SYT11-GBA Parkinson’s disease GWAS locus. Mov Disord 33:1821–1823. https://doi.org/10.1002/mds.103CrossRefPubMedPubMedCentral

Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69. https://doi.org/10.1038/nrn2038CrossRefPubMed

Bose S, Cho J (2017) Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders. Ageing Res Rev 35:155–175. https://doi.org/10.1016/j.arr.2016.09.004CrossRefPubMed

Brahmachari S, Ge P, Lee SH, Kim D, Karuppagounder SS, Kumar M, Mao X, Shin JH, Lee Y, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Ko HS (2016) Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. J Clin Invest 126:2970–2988. https://doi.org/10.1172/JCI85456CrossRefPubMedPubMedCentral

Brandt U (2006) Energy converting NADH: Quinone oxidoreductase (complex I). Annu Rev Biochem 75:69–92. https://doi.org/10.1146/annurev.biochem.75.103004.142539CrossRefPubMed

Carballo-Carbajal I, Laguna A, Romero-Giménez J, Cuadros T, Bové J, Martinez-Vicente M, Parent A, Gonzalez-Sepulveda M, Peñuelas N, Torra A, Rodríguez-Galván B, Ballabio A, Hasegawa T, Bortolozzi A, Gelpi E, Vila M (2019) Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis. Nat Commun 10:973. https://doi.org/10.1038/s41467-019-08858-yCrossRefPubMedPubMedCentral

Ceulemans AG, Zgavc T, Kooijman R, Hachimi-Idrissi S, Sarre S, Michotte Y (2010) The dual role of the neuroinflammatory response after ischemic stroke: Modulatory effects of hypothermia. J Neuroinflammation 7:74. https://doi.org/10.1186/1742-2094-7-74CrossRefPubMedPubMedCentral

Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5:235–245. https://doi.org/10.1016/S1474-4422(06)70373-8CrossRefPubMed

Cheret C, Gervais A, Lelli A, Colin C, Amar L, Ravassard P, Mallet J, Cumano A, Krause KH, Mallat M (2008) Neurotoxic activation of microglia is promoted by a nox1- dependent NADPH oxidase. J Neurosci 28:12039–12051. https://doi.org/10.1523/JNEUROSCI.3568-08.2008CrossRefPubMedPubMedCentral

Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909. https://doi.org/10.1016/s0896-6273(03)00568-3CrossRefPubMed

Davies KJA (2001) Degradation of oxidized proteins by the 20 s proteasome. Biochimie 83:301–310. https://doi.org/10.1016/s0300-9084(01)01250-0CrossRefPubMed

Dragicevic E, Poetschke C, Duda J, Schlaudraff F, Lammel S, Schiemann J, Fauler M, Hetzel A, Watanabe M, Lujan R, Malenka RC, Striessnig J, Liss B (2014) Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. Brain 137:2287–2302. https://doi.org/10.1093/brain/awu131CrossRefPubMedPubMedCentral

Dryanovski DI, Guzman JN, Xie Z, Galteri DJ, Volpicelli- Daley LA, Lee VM, Miller RJ, Schumacker PT, Surmeier DJ (2013) Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J Neurosci 33:10154–10164. https://doi.org/10.1523/JNEUROSCI.5311-12.2013CrossRefPubMedPubMedCentral

Dunn AR, Stout KA, Ozawa M, Lohr KM, Hoffman CA, Bernstein AI, Li Y, Wang M, Sgobio C, Sastry N, Cai H, Caudle WH, Miller GW (2017) Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci USA 114:E2253–E2262. https://doi.org/10.1073/pnas.1616892114CrossRefPubMed

Elstner M, Morris CM, Heim K, Bender A, Mehta D, Jaros E, Klopstock T, Meitinger T, Turnbull DM, Prokisch H (2011) Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol 122:75–86. https://doi.org/10.1007/s00401-011-0828-9CrossRefPubMed

Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL (2005) Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson’s disease. Prog Neurobiol 75:109–124. https://doi.org/10.1016/j.pneurobio.2005.02.001CrossRefPubMed

Gan-Or Z, Amshalom I, Kilarski LL, Bar-Shira A, Gana-Weisz M, Mirelman A, Marder K, Bressman S, Giladi N, Orr-Urtreger A (2015) Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 84:880–887. https://doi.org/10.1212/WNL.0000000000001315CrossRefPubMedPubMedCentral

Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T, Kedmi M, Giladi N, Orr-Urtreger A (2010) LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics 11:121–125. https://doi.org/10.1007/s10048-009-0198-9CrossRefPubMed

Gao X, Carroni M, Nussbaum-Krammer C, Mogk A, Nillegoda NB, Szlachcic A, Guilbride DL, Saibil HR, Mayer MP, Bukau B (2015) Human Hsp70 disaggregase reverses Parkinson’s-Linked α-synuclein amyloid fibrils. Mol Cell 59:781–793. https://doi.org/10.1016/j.molcel.2015.07.012CrossRefPubMedPubMedCentral

GBD 2016 Parkinson’s Disease Collaborators* (2018) Global, regional, and national burden of Parkinson’s disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:939–953. https://doi.org/10.1016/S1474-4422(18)30295-3CrossRef

George JL, Mok S, Moses D, Wilkins S, Bush AI, Cherny RA, Finkelstein DI (2009) Targeting the progression of Parkinson’s disease. Curr Neuropharmacol 7:9–36. https://doi.org/10.2174/157015909787602814CrossRefPubMedPubMedCentral

Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412. https://doi.org/10.1016/j.nbd.2005.08.002CrossRefPubMed

Goloubinoff P, Rios PDL (2007) The mechanism of Hsp70 chaperones: (entropic) pulling the models together. Trends Biochem Sci 32:372–380. https://doi.org/10.1016/j.tibs.2007.06.008CrossRefPubMed

Han Q, Cai T, Tagle DA, Li J (2010) Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci 67:353–368. https://doi.org/10.1007/s00018-009-0166-4CrossRefPubMed

Hantschel O, Superti-Furga G (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 5:33–44. https://doi.org/10.1038/nrm1280CrossRefPubMed

Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284. https://doi.org/10.1002/ana.10277CrossRefPubMed

Herrera AJ, Castano A, Venero JL, Cano J, Machado A (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7:429–447. https://doi.org/10.1006/nbdi.2000.0289CrossRefPubMed

Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334:345–348. https://doi.org/10.1038/334345a0CrossRefPubMed

Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debr´e P, Agid Y, Dugas B, Hirsch EC (1999) FcepsilonRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 19:3440–3447. https://doi.org/10.1523/JNEUROSCI.19-09-03440.1999CrossRefPubMedPubMedCentral

Hurley MJ, Brandon B, Gentleman SM, Dexter DT (2013) Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136:2077–2097. https://doi.org/10.1093/brain/awt134CrossRefPubMed

Hyun DH, Lee M, Halliwell B, Jenner P (2003) Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem 86:363–373. https://doi.org/10.1046/j.1471-4159.2003.01841.xCrossRefPubMed

Imam SZ, Trickler W, Kimura S, Binienda ZK, Paule MG, Slikker W Jr, Li S, Clark RA, Ali SF (2013) Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor ina murine Parkinson’s disease model. PLoS One 8:e65129. https://doi.org/10.1371/journal.pone.0065129CrossRefPubMedPubMedCentral

Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368–376. https://doi.org/10.1136/jnnp.2007.131045CrossRefPubMed

Jin H, Chen J, Li K, Zhang JR, Gu CC, Mao CJ, Yang YP, Wang F, Liu CF (2018) A novel p.L216I mutation in the glucocerebrosidase gene is associated with Parkinson’s disease in Han Chinese patients. Neurosci 674:66–69. https://doi.org/10.1016/j.neulet.2018.03.017CrossRef

Kampinga HH, Bergink S (2016) Heat shock proteins as potential targets for protective strategies in neurodegeneration. Lancet Neurol 15:748–759. https://doi.org/10.1016/S1474-4422(16)00099-5CrossRefPubMed

Kampinga HH, Hageman M, Vos MJ, Kubota H, Tanguay RM, Bruford ME, Cheetham EA, Chen B, Hightower LE (2009) Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 14:105–111. https://doi.org/10.1007/s12192-008-0068-7

Kanthasamy AG, Kitazawa M, Kaul S, Yang Y, Lahiri DK, Anantharam V, Kanthasamy A (2003) Proteolytic activation of proapoptotic kinase pkc δ is regulated by overexpression of Bcl_2. Ann N Y Acad Sci 1010:683–686. https://doi.org/10.1196/annals.1299.125CrossRefPubMed

Keeney PM, Xie J, Capaldi RA, Bennett JP Jr (2006) Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26:5256–5264. https://doi.org/10.1523/JNEUROSCI.0984-06.2006CrossRefPubMedPubMedCentral

Khaliq ZM, Bean BP (2010) Pacemaking in dopaminergic ventral tegmental area neurons: Depolarizing drive from background and voltage-dependent sodium conductances. J Neurosci 30:7401–7413. https://doi.org/10.1523/JNEUROSCI.0143-10.2010CrossRefPubMedPubMedCentral

Kirkinezos IG, Moraes CT (2001) Reactive oxygen species and mitochondrial diseases. Semin Cell Dev Biol 12:449–457. https://doi.org/10.1006/scdb.2001.0282CrossRefPubMed

Knyihar-Csillik E, Chadaide Z, Mihaly A, Krisztin-Peva B, Fenyo R, Vecsei L (2006) Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. Acta Neuropathol. 112:127–137. https://doi.org/10.1007/s00401-006-0086-4CrossRefPubMed

Knyihar-Csillik E, Csillik B, Pakaski M, Krisztin-Peva B, Dobo E, Okuno E, Vecsei L (2004) Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treatment. Neuroscience 126:899–914. https://doi.org/10.1016/j.neuroscience.2004.04.043

Koylu EO, Balkan B, Kuhar MJ, Pogun S (2006) Cocaine and Amphetamine Regulated Transcript (CART) and the stress response. Peptides 27:1956–1969. https://doi.org/10.1016/j.peptides.2006.03.032CrossRefPubMed

LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11:1214–1221. https://doi.org/10.1038/nm1314CrossRefPubMed

Ledeen RW, Wu G (2015) The multi-tasked life of GM1 ganglioside, a true factotum of nature. Trends Biochem Sci 40:407–418. https://doi.org/10.1016/j.tibs.2015.04.005CrossRefPubMed

Lee Y, Karuppagounder SS, Shin JH, Lee YII, Ko HS, Swing D, Jiang H, Kang SU, Lee BD, Kang HC, Kim D, Tessarollo L, Dawson VL, Dawson TM (2013) Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci 16:1392–1400. https://doi.org/10.1038/nn.3500CrossRefPubMedPubMedCentral

Lu W, Lee HK, Xiang C, Finniss S, Brodie C (2007) The phosphorylation of tyrosine 332 is necessary for the caspase 3- dependent cleavage of PKCδ and the regulation of cell apoptosis. Cell Signal 19:2165–2173. https://doi.org/10.1016/j.cellsig.2007.06.015CrossRefPubMed

Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, Halliday G, Hantschel O, Lashuel HA (2014) C-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinsons disease. Hum Mol Genet 23:2858–2879. https://doi.org/10.1093/hmg/ddt674CrossRefPubMedPubMedCentral

Mao P (2011) Potential antidepressant role of neurotransmitter CART: implications for mental disorders. Depress Res Treat 2011:762139. https://doi.org/10.1155/2011/762139CrossRefPubMedPubMedCentral

McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT (2002) TorsinA and heat shock proteins act as molecular chaperones: Suppression of α-synuclein aggregation. J Neurochem 83:846–854. https://doi.org/10.1046/j.1471-4159.2002.01190.xCrossRefPubMed

McNaught KS, Jenner P (2001) Proteasomal function is impaired in substantia nigra in Parkinson’s Disease. Neurosci Lett 297:191–194. https://doi.org/10.1016/s0304-3940(00)01701-8CrossRefPubMed

McNaught KStP, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol 179:38–46. https://doi.org/10.1006/exnr.2002.8050CrossRefPubMed

Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1beta, IL-2, IL-4, IL 6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett 211:13–16. https://doi.org/10.1016/0304-3940(96)12706-3CrossRefPubMed

Momtaz S, Memariani Z, El-Senduny FF, Sanadgol N, Golab F, Katebi M, Abdolghaffari AM, Farzaei MH, Abdollahi M (2020) Targeting ubiquitin-proteasome pathway by natural products: Novel therapeutic strategy for treatment of neurodegenerative diseases. Front Physiol 11:361. https://doi.org/10.3389/fphys.2020.00361CrossRefPubMedPubMedCentral

Moresco EMY, Donaldson S, Williamson A, Koleske AJ (2005) Integrin mediated dendrite branch maintenance requires Abelson (Abl) family kinases. J Neurosci 25:6105–6118. https://doi.org/10.1523/JNEUROSCICrossRefPubMedPubMedCentral

Morimoto RI (1998) Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev 12:3788–3796. https://doi.org/10.1101/gad.12.24.3788CrossRefPubMed

Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62:218–229. https://doi.org/10.1016/j.neuron.2009.01.033CrossRefPubMedPubMedCentral

Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochem J 417:1–13. https://doi.org/10.1042/BJ20081386CrossRefPubMed

Nillegoda NB, Bukau B (2015) Metazoan Hsp70-based protein disaggregases: emergence and mechanisms. Front Mol Biosci 2:1–12. https://doi.org/10.3389/fmolb.2015.00057CrossRef

Olanow CW, McNaught KS (2006) Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord 21:1806–1823. https://doi.org/10.1002/mds.21013CrossRefPubMed

Qi X, Mochly-Rosen D (2008) The PKCδ-Abl complex communicates ER stress to the mitochondria-an essential step in subsequent apoptosis. J Cell Sci 121:804–813. https://doi.org/10.1242/jcs.024653CrossRefPubMed

Qian L, Flood PM, Hong JS (2010) Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J Neural Transm 117:971–979. https://doi.org/10.1007/s00702-010-0428-1CrossRefPubMedPubMedCentral

Ramsey TL, Liu Q, Massey BW, Brennan MD (2013) Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study. Schizophr Res 149(1–3):21–25. https://doi.org/10.1016/j.schres.2013.07.008CrossRefPubMed

Ruskey JA, Greenbaum L, Ronciere L, Alam A, Spiegelman D, Liong C, Levy OA, Waters C, Fahn S, Marder KS, Chung W, Yahalom G, Israeli-Korn S, Livneh V, Fay-Karmon T, Alcalay RN, Hassin-Baer S, Gan-Or Z (2019) Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson’s disease. Eur J Med Genet 62:65–69. https://doi.org/10.1016/j.ejmg.2018.05.005CrossRefPubMed

Santens P, Boon P, Van Roost D, Caemaert J (2003) The pathophysiology of motor symptoms in Parkinson’s disease. Acta Neurol Belg 103:129–134PubMed

Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du WA (2013) randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson’s disease patients. J Neurol Sci 324:140–148. https://doi.org/10.1016/j.jns.2012.10.024CrossRefPubMed

Shamoto-Nagai M, Maruyama W, Kato Y, Isobe K, Tanaka M, Naoi M, Osawa T (2003) An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 74:589–597. https://doi.org/10.1002/jnr.10777CrossRefPubMed

Shin JH, Ko HS, Kang H, Lee Y, Lee YII, Pletinkova O, Troconso JC, Dawson VL, Dawson TM (2011) PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell 144:689–702. https://doi.org/10.1016/j.cell.2011.02.010CrossRefPubMedPubMedCentral

Sirvent A, Benistant C, Roche S (2012) Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res 2:357–371PubMedPubMedCentral

Sulzer D, Mosharov E, Talloczy Z, Zucca FA, Simon JD, Zecca L (2008) Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J Neurochem 106:24–36. https://doi.org/10.1111/j.1471-4159.2008.05385.xCrossRefPubMedPubMedCentral

Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A. 97:11869–11874. https://doi.org/10.1073/pnas.97.22.11869CrossRefPubMedPubMedCentral

Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT (2011) The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson’s disease. Neuroscience 198:221–231. https://doi.org/10.1016/j.neuroscience.2011.08.045

Tanabe A, Yamamura Y, Kasahara J, Morigaki R, Kaji R, Goto S (2014) A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease. Front Cell Neurosci 8:124. https://doi.org/10.3389/fncel.2014.00050CrossRef

Thaler A, Bregman N, Gurevich T, Shiner T, Dror Y, Zmira O, Gan-Or Z, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A (2018) Parkinson’s disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism Relat Disord 55:45–49. https://doi.org/10.1016/j.parkreldis.2018.05.009CrossRefPubMed

Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG (2003) Ubiquitination of alpha-synuclein in Lewy Bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 278:44405–44411. https://doi.org/10.1074/jbc.M308041200CrossRefPubMed

Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552:335–344. https://doi.org/10.1113/jphysiol.2003.049478CrossRefPubMedPubMedCentral

Turrens JF, Boveris A (1990) Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 191:421–427. https://doi.org/10.1042/bj1910421CrossRef

Votyakova TV, Reynolds I (2001) ∆Ψm-dependent and -independent production of reactive oxygen species by rat brain mitochondria. J Neurochem 79:266–277. https://doi.org/10.1046/j.1471-4159.2001.00548.xCrossRefPubMed

Yanik T, Dominguez G, Kuhar MJ, Del Giudice EM, Loh YP (2006) The Leu34Phe ProCART mutation leads to cocaine- and amphetamine-regulated transcript (CART) deficiency: A possible cause for obesity in humans. Endocrinology 147:39–43. https://doi.org/10.1210/en.2005-0812CrossRefPubMed

Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, Lipton SA (2004) Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A 101:10810–10814. https://doi.org/10.1073/pnas.0404161101CrossRefPubMedPubMedCentral

Zadori D, Nyiri G, Szonyi A, Szatmari I, Fulop F, Toldi J, Freund TF, Vecsei L, Klivenyi P (2010) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease. J Neural Transm 118:865–875. https://doi.org/10.1007/s00702-010-0573-6CrossRefPubMed

Zhang M, Han L, Xu Y (2011) Roles of cocaine- and amphetamine-regulated transcript in the central nervous system. Clin Exp Pharmacol Physiol 39:586–592. https://doi.org/10.1111/j.1440-1681.2011.05642.xCrossRef

Titel: Current and emerging therapeutic targets for Parkinson’s disease
verfasst von: Tanvi Pingale
Girdhari Lal Gupta
Publikationsdatum: 22.10.2020
Verlag: Springer US
Erschienen in: Metabolic Brain Disease / Ausgabe 1/2021
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-020-00636-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Linking chronic kidney disease and Parkinson’s disease: a literature review

Epilepsy in inherited neurotransmitter disorders: Spotlights onpathophysiology and clinical management

Circulating sortilin levels are associated with inflammation in patients with moyamoya disease

Insulin resistance: a connecting link between Alzheimer’s disease and metabolic disorder